RECENT SUCCESS

Pulse Biosciences

CO-FOUNDED: 2014

Delivering Nanosecond Pulses of Energy to Non-Thermal Cells

Nano-Pulse Stimulation (NPS™) is a proprietary technology that delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. First documented in 2001 at Old Dominion University and USC, these ultrafast electrical energy pulses
have pulse durations from billionths up to a millionth of a second. When applied to targeted tissue, NPS energy pulses enter cells and alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum. The cascade of intracellular disruption leads to
regulated cell death (RCD).” RCD is a process exhibited by cells in the human body when they undergo stress and are unable to restore cellular homeostasis.

About Pulse Biosciences

Pulse Biosciences (NASDAQ: PLSE) is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to
treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model.

Up next – Invizyne Technologies

PatentVest Logo

Harnessing the power of nature to create tomorrow’s molecules!

Invizyne, a partner company, was created in early 2019, with the vision of taking nature’s building blocks to make molecules of interest, effectively simplifying nature.